Physician profile
Udeme D Ekong
NPI 1376502492
$23,914.77
in general payments reported to CMS, 2019-2025
5 companies · $7,583 in 2025
The $7,583 reported for 2025 was more than what 77% of Pediatric Transplant Hepatology providers received nationally (typical 2025 total: $425).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,259 · 2023: $4,963 · 2024: $9,110 · 2025: $7,583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Honoraria: $3,750 · Travel and Lodging: $3,720 · Food and Beverage: $1,466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,720.00 |
| Honoraria | $3,750.00 |
| Travel and Lodging | $3,719.92 |
| Food and Beverage | $1,466.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $14,842.24 | 2022-2025 | Livmarli, Cholbam |
| Pierre Fabre Pharmaceuticals, INC. | $5,105.43 | 2025 | |
| Mallinckrodt Hospital Products INC. | $3,720.00 | 2024 | Terlivaz |
| Alcresta Therapeutics, INC. | $247.10 | 2025 | Relizorb |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Udeme Ekong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.